Airtime is crucial for high-rotation tricks in snowboard halfpipe performance, significantly impacting trick difficulty, the primary judging criterion. This study aims to enhance the detection of take-off and landing events using inertial measurement unit (IMU) data in conjunction with machine learning algorithms since manual video-based methods are too time-consuming. Eight elite German National Team snowboarders performed 626 halfpipe tricks, recorded by two IMUs at the lateral lower legs and a video camera.
View Article and Find Full Text PDFBackground: Recently, we could show that the co-mutations of + , + and + + lead to a significantly shorter median overall survival (mOS) across treatments by analyzing multiple datasets. , a tumor suppressor gene, plays a crucial role in regulating cell cycle progression. Its mutations occur in approximately 40-50% of non-small lung cancer (NSCLC).
View Article and Find Full Text PDFObjectives: Mutations in STK11 (STK11) and KEAP1 (KEAP1) occur frequently in non-small cell lung cancer (NSCLC) and are often co-mutated with KRAS. Several studies linked the co-occurrence of KRAS + STK11, as well as KRAS + KEAP1 to reduced response to immune checkpoint inhibitors (ICI) and even a negative impact on survival. Data focusing STK11 + KEAP1 co-mutations or the triple mutation (KRAS + STK11 + KEAP1) are scarce.
View Article and Find Full Text PDFOverexpression of the dihydrolipoamide S-succinyltransferase () is associated with poor outcome in neuroblastoma patients and triple-negative breast cancer (TNBC) and specifically with the oxidative phosphorylation (OXPHOS) pathway. Inhibitors of OXPHOS were previously suggested as a potential therapeutic strategy for a subset of patients with high-risk neuroblastoma. Here, we tested if cell lines with amplifications or high mRNA levels were associated with sensitivity to 250 drugs from the Genomics of Drug Sensitivity in Cancer (GDSC) dataset by comparing them to cell lines without these changes.
View Article and Find Full Text PDFPurpose: A wide therapeutic repertoire has become available to oncologists including radio- and chemotherapy, small molecules and monoclonal antibodies. However, drug efficacy can be limited by genetic heterogeneity. Here, we designed a webtool that facilitates the data analysis of the in vitro drug sensitivity data on 265 approved compounds from the GDSC database in association with a plethora of genetic changes documented for 1001 cell lines in the CCLE data.
View Article and Find Full Text PDF